BR112019024472A2 - Derivados cliváveis de lipo-glicopeptídeo e suas utilizações - Google Patents

Derivados cliváveis de lipo-glicopeptídeo e suas utilizações Download PDF

Info

Publication number
BR112019024472A2
BR112019024472A2 BR112019024472-7A BR112019024472A BR112019024472A2 BR 112019024472 A2 BR112019024472 A2 BR 112019024472A2 BR 112019024472 A BR112019024472 A BR 112019024472A BR 112019024472 A2 BR112019024472 A2 BR 112019024472A2
Authority
BR
Brazil
Prior art keywords
glycopeptide
lipo
clivable
lgpc
derivatives
Prior art date
Application number
BR112019024472-7A
Other languages
English (en)
Inventor
Heckler Ryan
Konicek Donna
Plaunt Adam
Malinin Vladimir
Perkins Walter
Original Assignee
Insmed Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Incorporated filed Critical Insmed Incorporated
Publication of BR112019024472A2 publication Critical patent/BR112019024472A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção fornece certos derivados cliváveis por lipo-glicopeptídeo e métodos para a utilização dos mesmos para o tratamento de infecções bacterianas, por exemplo, infecções bacterianas pulmonares. os derivados de lgpc incluem uma porção clivável que, em certas modalidades, é projetada para permitir a captação celular e/ou uma depuração mais rápida do metabólito glicopeptídeo (isto é, o glicopeptídeo clivado) a partir do sítio de administração (por exemplo, o pulmão) em comparação com a lgpc não clivado.
BR112019024472-7A 2017-05-22 2018-05-22 Derivados cliváveis de lipo-glicopeptídeo e suas utilizações BR112019024472A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762509378P 2017-05-22 2017-05-22
US62/509,378 2017-05-22
US201762518280P 2017-06-12 2017-06-12
US62/518,280 2017-06-12
US201762560413P 2017-09-19 2017-09-19
US62/560,413 2017-09-19
PCT/US2018/033963 WO2018217808A1 (en) 2017-05-22 2018-05-22 Lipo-glycopeptide cleavable derivatives and uses thereof

Publications (1)

Publication Number Publication Date
BR112019024472A2 true BR112019024472A2 (pt) 2020-06-16

Family

ID=64395938

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112019024549A BR112019024549A2 (pt) 2017-05-22 2018-05-22 compostos derivados de glicopeptídeo e usos dos mesmos
BR112019024472-7A BR112019024472A2 (pt) 2017-05-22 2018-05-22 Derivados cliváveis de lipo-glicopeptídeo e suas utilizações

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112019024549A BR112019024549A2 (pt) 2017-05-22 2018-05-22 compostos derivados de glicopeptídeo e usos dos mesmos

Country Status (11)

Country Link
US (3) US20200368312A1 (pt)
EP (2) EP3630154A4 (pt)
JP (2) JP7165146B2 (pt)
KR (2) KR102661790B1 (pt)
CN (2) CN110891590B (pt)
AU (2) AU2018271873B2 (pt)
BR (2) BR112019024549A2 (pt)
CA (2) CA3062570A1 (pt)
GB (2) GB2577419B (pt)
IL (2) IL270685B (pt)
WO (2) WO2018217800A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5548121B2 (ja) 2007-05-14 2014-07-16 リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク バイオフィルム中の細菌細胞における生理学的分散応答の誘導
GB2577419B (en) 2017-05-22 2022-08-17 Insmed Inc Lipo-glycopeptide cleavable derivatives and uses thereof
NL2023883B1 (en) * 2019-09-24 2021-04-26 Univ Leiden Antibiotic compounds
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
US20240024411A1 (en) * 2021-11-24 2024-01-25 Cumberland Pharmaceuticals Inc. Methods for the prevention or treatment of anthrax infection

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639433A (en) 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
EP0273727A3 (en) * 1986-12-30 1990-01-17 Smithkline Beecham Corporation Glycosylated glycopeptides
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
PT101450B (pt) 1994-02-02 1999-11-30 Hovione Produtos Farmaceuticos Novo dispositivo para inalacao
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
WO1998029141A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
WO1999016420A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
PL195212B1 (pl) 1997-09-29 2007-08-31 Nektar Therapeutics Preparat bioaktywny w postaci proszku i sposób jego wytwarzania
US6518242B1 (en) * 1998-02-20 2003-02-11 Theravance, Inc. Derivatives of glycopeptide antibacterial agents
EP1085846A2 (en) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
UA73924C2 (en) 1998-10-09 2005-10-17 Nektar Therapeutics Device for delivering active agent formulation to lungs of human patient
PT1140993E (pt) * 1998-12-23 2003-10-31 Theravance Inc Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos
JP4377076B2 (ja) 1999-05-28 2009-12-02 ネクター セラピューティクス 噴霧化された薬物の計量された量を投与する装置と方法
US6606992B1 (en) 1999-06-30 2003-08-19 Nektar Therapeutics Systems and methods for aerosolizing pharmaceutical formulations
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
AU2001238020A1 (en) 2000-02-04 2001-08-14 Advanced Medicine, Inc. Glycopeptide derivatives having antibiotic activity
AU3818001A (en) 2000-02-11 2001-08-20 Lilly Co Eli Selective n-acylation of a82846 glycopeptide analogs
CA2382133C (en) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
TWI312785B (en) * 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
AU2003287605A1 (en) 2002-11-12 2004-06-03 Enzon Pharmaceuticals, Inc. Polymeric prodrugs of vancomycin
JP2006528704A (ja) * 2003-05-27 2006-12-21 セラヴァンス インコーポレーテッド グリコペプチド抗細菌剤と組み合わせたポリエンマクロライド抗真菌剤の使用
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
US20070185015A1 (en) 2005-02-28 2007-08-09 Chiron Corporation and North China Pharmaceutical Corporation Semi-synthetic desmethyl-vancomycin-based glycopeptides with antibiotic activity
US7632918B2 (en) * 2005-02-28 2009-12-15 Novartis Vaccines And Diagnostics, Inc. Semi-synthetic glycopeptides with antibiotic activity
BRPI0817311A2 (pt) * 2007-09-25 2015-03-17 Novartis Ag Tratamento de doenças pulmonares com medicamentos em aerossol tais como a vancomicina
EP2214645A4 (en) * 2007-10-23 2013-09-25 Transave Inc LIPOSOMAL VANCOMYCIN PREPARATIONS
CN101959849A (zh) * 2007-12-26 2011-01-26 利德治疗公司 作为抗菌剂的新型半合成糖肽
US20100105607A1 (en) * 2008-10-24 2010-04-29 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
JP2012522009A (ja) * 2009-03-26 2012-09-20 パルマトリックス，インコーポレイテッド 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法
JP2012525391A (ja) * 2009-04-28 2012-10-22 ターガンタ セラピューティクス コーポレイション オリタバンシンを用いた細菌感染の治療方法
SG195038A1 (en) 2011-05-19 2013-12-30 Savara Inc Dry powder vancomycin compositions and associated methods
US9572774B2 (en) * 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
EP2739289B1 (en) 2011-08-05 2020-05-06 The Scripps Research Institute Glycopeptide antibiotic analogs effective against vancomycin-resistant bacterial strains
EP2852391B1 (en) * 2012-05-21 2021-11-17 Insmed Incorporated Systems for treating pulmonary infections
RU2018135921A (ru) 2012-11-29 2019-02-05 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
GB201402267D0 (en) * 2014-02-10 2014-03-26 Cambridge Entpr Ltd Antibacterial agents
CN105085636B (zh) * 2014-05-19 2020-05-01 中国医学科学院药物研究所 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用
CA2954653C (en) 2014-07-10 2023-01-24 The Scripps Research Institute N-(hydrophobe-substituted)vancosaminyl [.psi.[c(=nh)nh]tpg4]vancomycin and [.psi.[ch2nh]tpg4]vancomycin
CN107325159A (zh) 2016-04-29 2017-11-07 中国科学院上海药物研究所 一类万古霉素衍生物、其制备方法、药物组合物和用途
WO2018008197A1 (ja) 2016-07-07 2018-01-11 日東電工株式会社 反射層および蛍光体層付光半導体素子
WO2018081797A1 (en) 2016-10-31 2018-05-03 The Scripps Research Institute Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability
GB2577419B (en) * 2017-05-22 2022-08-17 Insmed Inc Lipo-glycopeptide cleavable derivatives and uses thereof

Also Published As

Publication number Publication date
EP3630154A4 (en) 2021-03-10
GB201917677D0 (en) 2020-01-15
GB201917675D0 (en) 2020-01-15
US20200368312A1 (en) 2020-11-26
JP2020520986A (ja) 2020-07-16
JP7210476B2 (ja) 2023-01-23
GB2577420B (en) 2022-07-06
US20200155640A1 (en) 2020-05-21
JP7165146B2 (ja) 2022-11-02
CA3062570A1 (en) 2018-11-29
IL270685B (en) 2022-09-01
AU2018271873A1 (en) 2019-11-28
CN110891590B (zh) 2023-07-18
GB2577420A (en) 2020-03-25
AU2018273887B2 (en) 2022-09-08
IL270686B (en) 2022-09-01
US11857597B2 (en) 2024-01-02
IL270685A (pt) 2019-12-31
CN110891590A (zh) 2020-03-17
KR20200027922A (ko) 2020-03-13
CA3062567A1 (en) 2018-11-29
EP3634464A4 (en) 2021-04-07
WO2018217808A1 (en) 2018-11-29
AU2018273887A1 (en) 2019-11-28
AU2018271873B2 (en) 2023-11-02
WO2018217800A1 (en) 2018-11-29
KR102661786B1 (ko) 2024-04-26
KR20200026803A (ko) 2020-03-11
KR102661790B1 (ko) 2024-04-26
CN110996984A (zh) 2020-04-10
US11071769B2 (en) 2021-07-27
GB2577419A (en) 2020-03-25
JP2020520987A (ja) 2020-07-16
EP3634464A1 (en) 2020-04-15
BR112019024549A2 (pt) 2020-06-09
GB2577419B (en) 2022-08-17
EP3630154A1 (en) 2020-04-08
IL270686A (pt) 2019-12-31
US20220133843A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
BR112019024472A2 (pt) Derivados cliváveis de lipo-glicopeptídeo e suas utilizações
CL2018002009A1 (es) Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.
BR112017018316A2 (pt) composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral
BR112018005048B8 (pt) uso de um composto antiviral ou sal do mesmo para o tratamento de uma infecção por coronaviridae
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112019002275A2 (pt) inibidores aminopirimidina de ssaos
BR112018013218A2 (pt) derivado de acrilanilida, método de preparação e aplicação do mesmo na farmácia
BR112018004175A2 (pt) novo composto pirazolo[3,4-d]pirimidina ou sal deste
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
GT201600086A (es) Pirrolo[12-f][1,2,4]triazinas útiles para tratar infecciones por el virus sincitial respiratorio
BR112017001162A2 (pt) métodos para tratar paramixovírus
BR112016029713A8 (pt) uso de uma carboximetilcelulose reticulada e uso de um agente gelificante
BR112015016793A2 (pt) compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim
BR112014006988A2 (pt) sistema de fraturamento ajustável
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BR112017013661A8 (pt) Conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica
BR112017020780A2 (pt) métodos de administração de inibidores de glutaminase
BR112017018643A2 (pt) "derivados de tetra-hidrotiazepina bicíclicos úteis, composição farmacêutica compreendendo os mesmos, seu uso, e método in vitro ou ex vivo para a produção de células imunes ativadas"
NI201500115A (es) Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112012027648A2 (pt) composto medicamento, método para profilaxia ou tratamento de doença, e, uso de composto
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112019006216A2 (pt) compostos de p2x3 e/ou p2x2/3 e métodos
BR112018076528A2 (pt) composições e métodos para diagnosticar cânceres de pulmão usando perfis de expressão gênica

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]